Clinical Trial Update: Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating neoadjuvant or adjuvant epirubicin, cyclophosphamide, and paclitaxel in women with Stage I–III breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED